These results indicate that FGFR1 activation is essential for the development of tolerance to the combination of osimertinib and volasertib in EGFR-mutant NSCLC cells, highlighting FGFR1 signaling as a critical feedback-mediated mechanism that warrants further investigation. The gene discussed is FGFR1; the disease is non-small cell lung carcinoma.